These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36454709)

  • 81. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Identification of preclinical dementia according to ATN classification for stratified trial recruitment: A machine learning approach.
    Koychev I; Marinov E; Young S; Lazarova S; Grigorova D; Palejev D
    PLoS One; 2023; 18(10):e0288039. PubMed ID: 37856502
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
    Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
    Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
    Boerwinkle AH; Wisch JK; Chen CD; Gordon BA; Butt OH; Schindler SE; Sutphen C; Flores S; Dincer A; Benzinger TLS; Fagan AM; Morris JC; Ances BM
    Neurology; 2021 Jul; 97(1):e76-e87. PubMed ID: 33931538
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer's disease.
    Lagarde J; Olivieri P; Tonietto M; Tissot C; Rivals I; Gervais P; Caillé F; Moussion M; Bottlaender M; Sarazin M
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):459-467. PubMed ID: 35228270
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.
    Digma LA; Winer JR; Greicius MD
    J Alzheimers Dis; 2024; 97(2):567-572. PubMed ID: 38250779
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease.
    Pang M; Gabelle A; Saha-Chaudhuri P; Huijbers W; Gafson A; Matthews PM; Tian L; Rubino I; Hughes R; de Moor C; Belachew S; Shen C
    Alzheimers Dement; 2024 Feb; 20(2):1102-1111. PubMed ID: 37882364
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.
    Cummings J; Aisen P; Lemere C; Atri A; Sabbagh M; Salloway S
    Alzheimers Res Ther; 2021 May; 13(1):98. PubMed ID: 33971962
    [No Abstract]   [Full Text] [Related]  

  • 95. Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.
    Wolters FJ; Labrecque JA
    Alzheimers Dement; 2024 Apr; 20(4):3119-3125. PubMed ID: 38380503
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.
    Cummings J
    Alzheimers Dement; 2019 Jan; 15(1):172-178. PubMed ID: 29936146
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Once upon a time, the Amyloid Cascade Hypothesis.
    Granzotto A; Sensi SL
    Ageing Res Rev; 2024 Jan; 93():102161. PubMed ID: 38065226
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
    Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB;
    Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?
    Korologou-Linden R; Kalsi J; Kafetsouli D; Olawale A; Iwata A; Wingfield D; Mummery D; Hayhoe B; Robinson O; Majeed A; Middleton LT
    J Prev Alzheimers Dis; 2024; 11(4):897-902. PubMed ID: 39044500
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Alzheimer's disease: From immunotherapy to immunoprevention.
    Jucker M; Walker LC
    Cell; 2023 Sep; 186(20):4260-4270. PubMed ID: 37729908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.